Table 3.

Major Adverse Cardiovascular Events and GUSTO Moderate/Severe Bleeding Rates Stratified by Mortality and Bleeding Risks

Predicted Risk	MACE (Pras vs Clop)			Moderate/Severe Bleeding (Pras vs Clop)
	Unadjusted (%)	Adj. HR	95% CI	Unadjusted (%)	Adj. HR	95% CI
High mortality N=5396	14.8 vs 18.8a	1.16	0.89 to 1.50	3.8 vs 5.0	1.20	0.70 to 2.08
Low mortality N=6573	12.2 vs 15.5a	0.94	0.77 to 1.15	2.0 vs 2.4	1.55	0.89 to 2.70
High bleeding N=5532	17.8 vs 20.8a	1.18	0.94 to 1.48	4.3 vs 5.5	1.47	0.91 to 2.38
Low bleeding N=6437	10.4 vs 13.6a	0.88	0.70 to 1.10	1.6 vs 1.9	0.99	0.60 to 1.63
High mortality
Low bleeding N=1755	10.6 vs 13.9	1.03	0.61 to 1.76	2.4 vs 3.1	0.74	0.34 to 1.61
High bleeding N=3641	17.4 vs 21.0	1.21	0.91 to 1.62	4.6 vs 5.9	1.34	0.72 to 2.48
Low mortality
High bleeding N=1891	18.3 vs 20.3	1.13	0.80 to 1.62	3.9 vs 4.7	1.83	0.85 to 3.95
Low bleeding N=4682	10.3 vs 13.5a	0.83	0.67 to 1.03	1.4 vs 1.4	1.20	0.63 to 2.29

Clop indicates clopidogrel; GUSTO, Global Utilization of Streptokinase and t‐PA for Occluded Coronary Arteries; HR, hazard ratio; MACE, major adverse cardiovascular events; Pras, prasugrel.

^a P≤0.05.